ArticleBMC pulmonary medicine2024
Protocol and research program of the European registry and biobank for interstitial lung diseases (eurILDreg).
Article in BMC pulmonary medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02951416 (The European IPF Registry - an Internet-based, Pan-European Registry Linked to the European IPF Biobank), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The European IPF Registry - an Internet-based, Pan-European Registry Linked to the European IPF Biobank (eurIPFbank)
Who cites it
11 citing papers in PubMed.
- Post-transplant trajectories of the CRP-to-albumin ratio identify a late-emerging high-risk phenotype in interstitial lung disease.BMC pulmonary medicine · 2026Observational
- Beyond Diffusion Capacity: Continuous Exercise Oximetry Reveals Phenotype-Related Cardiopulmonary Signals in Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis-A eurILDreg Pilot Study.Journal of clinical medicine · 2026Article
- Peri-transplant frailty changes impact survival in interstitial lung diseases.ERJ open research · 2026Article
- Sex-Dependent Integration of Symptoms and Functional Vulnerability in Interstitial Lung Disease: eurILDreg Study.Respiration; international review of thoracic diseases · 2026Article
- The Patient Journey in Interstitial Lung Disease: Mobility, Independence, and Psychological Burden.Journal of clinical medicine · 2025Article
- Treatable Traits in Pediatric Interstitial Lung Diseases: Bridging the Gap to Tailored Therapeutics.Journal of clinical medicine · 2025Review
- Pulmonary Hypertension Drives Prognosis in Idiopathic Pulmonary Fibrosis: Insights from the European IPF Registry.Journal of clinical medicine · 2025Article
- Beyond Labels: Can Biomarkers and Treatable Traits Revolutionize Interstitial Lung Disease Care?Biomedicines · 2025Article
- Dual Impacts of Lung Transplantation on the Recovery and Comorbidity of Interstitial Lung Diseases: A Longitudinal Assessment of the Benefits and Burden.Journal of clinical medicine · 2025Article
- An update on diagnosis and treatments of childhood interstitial lung diseases.Breathe (Sheffield, England) · 2025Review
- European ILD registry algorithm for self-assessment in interstitial lung diseases (eurILDreg ASA-ILD).PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsInterstitial lung diseases (ILDs), encompassing both pediatric and adult cases, present a diverse spectrum of chronic conditions with variable prognosis. Despite limited therapeutic options beyond antifibrotic drugs and immunosuppressants, accurate diagnosis is challenging, often necessitating invasive procedures that may not be feasible for certain patients. Drawn against this background, experts across pediatric and adult ILD fields have joined forces in the RARE-ILD initiative to pioneer novel non-invasive diagnostic algorithms and biomarkers. Collaborating with the RARE-ILD consortium, the eurILDreg aims to comprehensively describe different ILDs, analyze genetically defined forms across age groups, create innovative diagnostic and therapeutic biomarkers, and employ artificial intelligence for data analysis.
methodsThe foundation of eurILDreg is built on a comprehensive parameter list developed and adopted by clinical experts, encompassing over 1,800 distinct parameters related to patient history, clinical examinations, diagnosis, lung function and biospecimen collection. This robust dataset is further enriched with daily assessments captured through the patientMpower app, including handheld spirometry and exercise tests, conducted on approximately 350 patients over the course of a year. This approach involves app-based daily assessments of quality of life, symptom tracking, handheld spirometry, saturation measurement, and the 1-min sit-to-stand test (1-STST). Additionally, pediatric data from the ChILD-EU registry will be integrated into the RARE-ILD Data Warehouse, with the ultimate goal of including a total of 4.000 ILD patients and over 100.000 biospecimen. DISCUSSION: The collaborative efforts within the consortium are poised to streamline research endeavors significantly, promising to advance patient-centered care, foster innovation, and shape the future landscape of interstitial lung disease research and healthcare practices.
trial registrationEurILDreg is registered in the German Clinical Trials Register (DRKS 00028968, 26.07.2022), and eurIPFreg is registered in ClinicalTrials.gov (NCT02951416).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.